Sign In
Buy LRMR
$4.11
+0.130 (+3.27%)
At Close: Aug 04, 2026
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
12:25pm, Wednesday, 22'nd May 2024
The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
04:05pm, Monday, 20'th May 2024
BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disease
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
07:00am, Thursday, 09'th May 2024
BALA CYNWYD, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare d
BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
BALA CYNWYD, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
04:05pm, Wednesday, 06'th Mar 2024
BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rar
BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
06:15am, Wednesday, 14'th Feb 2024
BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics Announces Proposed Underwritten Public Offering
04:18pm, Tuesday, 13'th Feb 2024
BALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
01:15pm, Wednesday, 03'rd Jan 2024
Biotech could be poised to rebound in 2024. Wall Street thinks clinical and early commercial-stage drugmakers may be among the group's best performers this year.
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
07:00am, Tuesday, 14'th Nov 2023
BALA CYNWYD, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
04:05pm, Tuesday, 03'rd Oct 2023
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
04:05pm, Thursday, 31'st Aug 2023
BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
07:00am, Thursday, 10'th Aug 2023
BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
